Insider Selling: BioDelivery Sciences International, Inc. (BDSI) CFO Sells 64,155 Shares of Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De sold 64,155 shares of BioDelivery Sciences International stock in a transaction that occurred on Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the completion of the transaction, the chief financial officer now directly owns 97,731 shares in the company, valued at approximately $204,257.79. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of BDSI traded down $0.05 during mid-day trading on Friday, hitting $2.10. The company’s stock had a trading volume of 284,601 shares, compared to its average volume of 463,167. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37. BioDelivery Sciences International, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $3.60.

How to Become a New Pot Stock Millionaire

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). The business had revenue of $12.51 million during the quarter, compared to analyst estimates of $9.83 million. BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.74 EPS for the current year.

Several equities analysts have recently issued reports on BDSI shares. Seaport Global Securities started coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They issued a “buy” rating and a $5.00 price objective on the stock. Zacks Investment Research raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. ValuEngine cut shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. HC Wainwright set a $4.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, March 19th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 price objective on shares of BioDelivery Sciences International in a research note on Thursday, March 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. BioDelivery Sciences International presently has a consensus rating of “Buy” and a consensus price target of $4.25.

Several institutional investors have recently added to or reduced their stakes in BDSI. Northern Trust Corp increased its position in shares of BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after acquiring an additional 1,203 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of BioDelivery Sciences International in the third quarter worth approximately $116,000. Wells Fargo & Company MN increased its position in shares of BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares in the last quarter. Royce & Associates LP purchased a new position in shares of BioDelivery Sciences International in the third quarter worth approximately $3,814,000. Finally, Krilogy Financial LLC increased its position in shares of BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after acquiring an additional 30,000 shares in the last quarter. 45.82% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Insider Selling: BioDelivery Sciences International, Inc. (BDSI) CFO Sells 64,155 Shares of Stock” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3338179/insider-selling-biodelivery-sciences-international-inc-bdsi-cfo-sells-64155-shares-of-stock.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jeffrey R. Hines Acquires 557 Shares of The York Water Company  Stock
Jeffrey R. Hines Acquires 557 Shares of The York Water Company Stock
Motorcar Parts of America Inc.  Given Consensus Recommendation of “Hold” by Brokerages
Motorcar Parts of America Inc. Given Consensus Recommendation of “Hold” by Brokerages
Casa Systems  Receives Average Rating of “Buy” from Analysts
Casa Systems Receives Average Rating of “Buy” from Analysts
Dialog Semiconductor PLC  Given Average Rating of “Hold” by Brokerages
Dialog Semiconductor PLC Given Average Rating of “Hold” by Brokerages
Burberry  Given New GBX 1,865 Price Target at Berenberg Bank
Burberry Given New GBX 1,865 Price Target at Berenberg Bank
Investment Analysts’ Price Target Changes for April, 19th
Investment Analysts’ Price Target Changes for April, 19th


Leave a Reply

© 2006-2018 Ticker Report. Google+.